PLASMA CORTISONE IN THE METABOLIC SYNDROME

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 可的松的活性形式是皮质醇，一种在肾上腺中产生的物质。 皮质醇被肾脏灭活形成非活性可的松，可的松在肝脏和脂肪组织中被重新激活以改革活性皮质醇。 最近的证据表明，肥胖个体的脂肪细胞增加了重新激活可的松的酶的活性。 由于皮质醇的过度产生导致腹部肥胖，这可能是过度活跃的这种再激活过程是导致某些人肥胖恶化的原因。 为了确定这一途径的重要性，我们计划使用甘草提取物来阻断肾脏中可的松的形成。 如果可的松在脂肪细胞中的重新激活在引起腹部肥胖中是重要的，那么抑制可的松的形成应该会引起腹部脂肪的减少。 我们将研究12名腹部肥胖的女性。 6名受试者将接受甘草提取物治疗6个月，其他6名受试者将接受不含药物的药丸治疗6个月。 每名受试者将参加一项运动计划并遵循饮食。我们将在治疗前和治疗期间测量体重、腹部和全身脂肪含量、糖、胰岛素、胆固醇和血压。 甘草的已知副作用包括盐潴留，血压升高和钾流失。 为了防止这些副作用，我们将管理螺内酯沿着与甘草提取物。 螺内酯是甘草的高血压、盐保留和钾消耗作用的有效抑制剂。'

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The active form of cortisone is cortisol, a substance made in the adrenal glands. Cortisol is inactivated by the kidney to form inactive cortisone, and cortisone is reactivated in liver and fat tissue to reform active cortisol. Recent evidence suggests that fat cells in obese individuals have increased activity of the enzyme that reactivates cortisone. Since overproduction of cortisol causes abdominal obesity, it is possible that overactivity of this reactivation process is responsible for worsening obesity in some individuals. In order to determine the importance of this pathway, we plan to block the formation of cortisone in the kidney using a licorice extract. If reactivation of cortisone in fat cells is important in causing abdominal obesity, inhibition of cortisone formation should cause a decrease in abdominal fat. We will study twelve women with abdominal obesity. Six subjects will be treated with licorice extract for six months and the other six subjects will receive pills which do not contain medication for six months. Each subject will participate in an exercise program and will follow a diet. We will measure weight, abdominal and total body fat content, sugar, insulin, cholesterol and blood pressure before treatment and during treatment. Known side effects of licorice include salt retention, increased blood pressure and potassium loss. In order to prevent these side effects, we will administer spironolactone along with the licorice extract. Spironolactone is an effective inhibitor of the hypertensive, salt retaining and potassium wasting effects of licorice.'